このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Adjunctive Smart Phone Based Smoking Cessation Treatment

Participants will be recruited for the current study during their initial orientation visit to the Parkland Health and Hospital System, Stop Smoking Class and Clinic every Monday morning. Individuals who are interested and eligible for participation in this study will receive uC (Parkland smoking cessation program), plus a tailored, adaptive, smart phone delivered smoking cessation intervention. Participants will be followed weekly from 1 week pre-quit through 4 weeks post-quit. all participants will be asked to attend 6 weekly visits, 4 of these visits will include a thorough assessment that may be completed either before or after their scheduled Parkland treatment appointments. All participants will receive a smartphone at the 1 week pre-quit visit and they will be asked to carry it with them at all times. Participants will complete eMa assessments 5 times per day (4 random assessments + 1 daily dairy) for three consecutive weeks. Geographic location coordinates will be captured during each eMa assessment to link characteristics of the neighborhood environment (e.g., neighborhood socioeconomic status, proximity to tobacco outlets) with cessation-related outcomes. Participants will be compensated upon the return of the smartphone at visit 4 (2 weeks post-quit). Participants will be asked to attend a follow-up visit 12 weeks after their quit date. At this visit, participants will complete additional questionnaires and their smoking status will be assessed. Expired carbon monoxide and weight will also be measured.

調査の概要

詳細な説明

Research Supporting Study Objectives. Tobacco use is the leading cause of preventable death in the U.S. Over 443,000 deaths per year are attributable to smoking, with the leading causes of smoking-attributable death being cancer, cardiovascular diseases, and respiratory disease. Although the prevalence of smoking has declined to 20.6% among U.S. adults, 31.1% of those living in poverty are currently smoking. Numerous studies have shown that low SES and financial strain are associated with a reduced likelihood of smoking cessation. As such, lung cancer incidence is far greater among those with low education and who are living in poverty, relative to their higher SES counterparts. Although individuals of low SES are just as likely to attempt smoking cessation, they are less likely to succeed. As such, smoking cessation interventions for low SES populations have had limited success (e.g., biologically confirmed 7-day point prevalence abstinence rates of 7-13% at 6-month follow-up. Innovative smoking cessation interventions are needed to help reduce the rate of smoking in socioeconomically disadvantaged populations of smokers.

Ecological Momentary Assessment and Smoking Cessation Treatments. To date, most studies that have examined smoking and smoking cessation in socioeconomically disadvantaged smokers have used focus groups or traditional lab/clinic based assessment methodology. In the latter scenario, study participants arrive at a lab or clinic for their baseline visit and are asked to answer questions about their "average" or "recent" (e.g., over the past 2 weeks) mood, level of stress, and smoking urges. Participants return to the lab/clinic for follow-up visits and are asked to report thoughts, feelings, and activities that occurred weeks or even months earlier (e.g., "How stressed were you when you smoked your first cigarette after your quit date?"). This type of assessment methodology may result in biased and/or inaccurate estimates due to recall biases and errors in memory and only offers a gross understanding of how cessation symptoms effect smoking lapses and relapse. A more nuanced picture of these symptoms may offer important insights that may be used to create or improve cessation interventions for socioeconomically disadvantaged smokers, who face unique and substantial challenges in quitting smoking.

Ecological momentary assessment (EMA), in which handheld devices (e.g., smart phones) are used to capture moment to moment experience, is currently the most accurate way to measure phenomena in real time in natural settings. EMAs are often used to assess individuals at multiple time points throughout a day. Thus, momentary changes in key variables can be tracked and potentially used to initiate novel interventions. EMA research may facilitate a better understanding of the mechanisms involved in successful cessation attempts, those affecting smoking lapses, and those implicated in the transition from lapse to relapse. Although multiple studies have identified momentary predictors of smoking relapse to our knowledge, no studies have used a participant's responses to EMAs to automatically prompt tailored smoking cessation interventions. Using smart phones to detect high relapse risk situations and automatically deliver tailored smoking cessation treatments may help socioeconomically disadvantaged smokers quit.

研究の種類

介入

入学 (実際)

75

段階

  • 適用できない

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

Participants will be included in the study if they:

  1. earn a score greater than or equal to 4 on the Short REALM indicating greater than 6th grade English literacy level,
  2. are willing to quit smoking 7 days from their first visit,
  3. are greater than or equal to 18 years of age,
  4. have an expired CO level greater than or equal to 8 ppm suggestive of current smoking,
  5. are currently smoking greater than or equal to 5 cigarettes per day,
  6. are willing and able to attend 6 weekly sessions (i.e., week -1, quit day, week +1, week +2, week +3, week +4) and the 12 week follow-up session , and
  7. have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.

Exclusion Criteria:

Participants will be excluded from the study if they:

  1. are unwilling to quit smoking 7 days from their first visit,
  2. have already quit smoking,
  3. earn a score less than 4 on the Short REALM indicating less than or equal to 6th grade literacy level,
  4. produce an expired CO level less than 8 ppm,
  5. are currently smoking less than 5 cigarettes per day,
  6. are unwilling or unable to attend 7 assessment sessions,
  7. are less than 18 years of age, and/or
  8. have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Study Visits

The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.

Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete.

The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Smoking abstinence
時間枠:12 weeks
Evidence of abstinence from smoking confirmed by questionnaire.
12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jennifer Gonzalez、UT Southwestern Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2014年6月1日

一次修了 (実際)

2018年9月1日

研究の完了 (実際)

2018年9月1日

試験登録日

最初に提出

2017年2月9日

QC基準を満たした最初の提出物

2017年11月9日

最初の投稿 (実際)

2017年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2019年1月15日

QC基準を満たした最後の更新が送信されました

2019年1月11日

最終確認日

2019年1月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SCCC-PSO1Z14
  • STU 012014-012 (その他の識別子:UTSouthwestern Medical Center)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

高リスクがんの臨床試験

  • Institute of Hematology & Blood Diseases Hospital...
    Hebei Taihe Chunyu Biotechnology Co., Ltd
    募集
    形質細胞白血病 | Ultra High Risk MM(UHR-MM)、18〜70歳、ASCTに適しています。次のUHR-MM定義のいずれかを満たします | 細胞遺伝学の超高リスク | 一次難治 | 早期進行 | 非麻痺性髄外浸潤 | R2-ISS-IV /MPSS-IV
    中国
  • Novartis Pharmaceuticals
    終了しました
    メラノーマ | 高度なEGFR変異体非小さな細胞肺cancer(NSCLC) | KRAS G12変異NSCLC | 食道扁平上皮がん(SCC) | ヘッド/ネックSCC | 進行した胃腸間質腫瘍(GIST) | 進行したNRAS/BRAFT WT皮膚黒色腫
    アメリカ, 台湾, オランダ, カナダ, スペイン, シンガポール, イタリア, 日本, 韓国
  • Incyte Biosciences International Sàrl
    完了
    子宮頸癌 | 肝細胞癌 | 食道がん | 卵巣がん | 中皮腫 | 非小細胞肺がん (NSCLC) | 尿路上皮がん | メルケル細胞がん | びまん性大細胞型B細胞リンパ腫 | トリプルネガティブ乳がん | 腎細胞がん(RCC) | 小細胞肺がん(SCLC) | 頭頸部の扁平上皮癌(SCCHN) | マイクロサテライト不安定性 (MSI) - 高子宮内膜がん | 胃がん(胃および胃食道接合部[GEJ]を含む) | 黒色腫(ぶどう膜黒色腫を除く) | MSI-highの結腸直腸がん
    アメリカ
  • Jonsson Comprehensive Cancer Center
    National Cancer Institute (NCI); Highlight Therapeutics
    積極的、募集していない
    平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件
    アメリカ

Smart Phone Based Smoking Cessationの臨床試験

購読する